Patents by Inventor Shiming Peng
Shiming Peng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240383908Abstract: A synthesis and an application of a phosphatase degrader are provided. The phosphatase degrader is a compound represented by formula I, or a salt thereof, or a deuterated compound thereof, or a stereoisomer thereof, or a solvate thereof, or a hydrate thereof, or a prodrug thereof. The compound can be used as a phosphatase degrader, especially as an SHP2 protein degrader, can treat malignant diseases such as tumors, and has good application prospects.Type: ApplicationFiled: July 6, 2022Publication date: November 21, 2024Inventors: Lei FAN, Hua YU, Fei WANG, Chaowu AI, Kexin XU, Jing DU, Xingtai LIU, Ying PENG, Tongchuan LUO, Shiming PENG, Bin TAN, Daibiao XIAO, Yongxu HUO, Chengcheng LIU, Xinghai LI, Yuanwei CHEN
-
Publication number: 20210238127Abstract: The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.Type: ApplicationFiled: April 18, 2021Publication date: August 5, 2021Applicant: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Shiming Peng
-
Patent number: 10988440Abstract: The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.Type: GrantFiled: January 12, 2020Date of Patent: April 27, 2021Assignee: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Shiming Peng
-
Patent number: 10980766Abstract: The invention provides use of entacapone, an entacapone derivative or a stereoisomer, hydride, or pharmaceutically-acceptable salt thereof, in a person in need thereof, to treat or inhibit macular degeneration or age-related macular degeneration, and related compostions.Type: GrantFiled: February 22, 2019Date of Patent: April 20, 2021Assignee: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Shiming Peng
-
Patent number: 10682329Abstract: Obesity is inhibited by administering to a person in need thereof an effective amount of entacapone ((2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide), or a pharmaceutically-acceptable salt thereof, particularly in conjunction with a second, different anti-obesity medicament. Pharmaceutical compositions comprise entacapone copackaged or coformulated with a second, different anti-obesity medicament.Type: GrantFiled: June 26, 2018Date of Patent: June 16, 2020Assignee: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Gang Zhi, Jijie Chai, Shiming Peng, Nannan Hou
-
Publication number: 20200148628Abstract: The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.Type: ApplicationFiled: January 12, 2020Publication date: May 14, 2020Applicant: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Shiming Peng
-
Patent number: 10532976Abstract: The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.Type: GrantFiled: December 22, 2017Date of Patent: January 14, 2020Assignee: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Shiming Peng
-
Publication number: 20190183842Abstract: The invention provides use of entacapone, an entacapone derivative or a stereoisomer, hydride, or pharmaceutically-acceptable salt thereof, in a person in need thereof, to treat or inhibit macular degeneration or age-related macular degeneration, and related compostions.Type: ApplicationFiled: February 22, 2019Publication date: June 20, 2019Inventors: Niu Huang, Shiming Peng
-
Publication number: 20180303788Abstract: Obesity is inhibited by administering to a person in need thereof an effective amount of entacapone ((2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide), or a pharmaceutically-acceptable salt thereof, particularly in conjunction with a second, different anti-obesity medicament. Pharmaceutical compositions comprise entacapone copackaged or coformulated with a second, different anti-obesity medicament.Type: ApplicationFiled: June 26, 2018Publication date: October 25, 2018Applicant: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Gang Zhi, Jijie Chai, Shiming Peng, Nannan Hou
-
Patent number: 10004715Abstract: Obesity is inhibited by administering to a person in need thereof an effective amount of entacapone ((2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide), or a pharmaceutically-acceptable salt thereof, particularly in conjunction with a second, different anti-obesity medicament. Pharmaceutical compositions comprise entacapone copackaged or coformulated with a second, different anti-obesity medicament.Type: GrantFiled: January 4, 2014Date of Patent: June 26, 2018Assignee: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Gang Zhi, Jijie Chai, Shiming Peng, Nannan Hou
-
Publication number: 20180118665Abstract: The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.Type: ApplicationFiled: December 22, 2017Publication date: May 3, 2018Applicant: National Institute of Biological Sciences, BeijingInventors: Niu Huang, Shiming Peng
-
Publication number: 20140148383Abstract: Obesity is inhibited by administering to a person in need thereof an effective amount of entacapone ((2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide), or a pharmaceutically-acceptable salt thereof, particularly in conjunction with a second, different anti-obesity medicament. Pharmaceutical compositions comprise entacapone copackaged or coformulated with a second, different anti-obesity medicament.Type: ApplicationFiled: January 4, 2014Publication date: May 29, 2014Applicant: NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJINGInventors: Niu Huang, Gang Zhi, Jijie Chai, Shiming Peng, Nannan Hou
